Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), By End Use (Hospitals, Outpatient Facilities, Home Care, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Prostate Cancer Diagnostics Market Size

The global prostate cancer diagnostics market size was valued at USD 9.36 billion in 2025 and is projected to grow from USD 9.93 billion in 2026 to USD 15.95 billion by 2034, registering a CAGR of 6.1% during the forecast period from 2026 to 2034. North America dominated the prostate cancer diagnostics market with a market share of 39.2% in 2025.

The growing prevalence of prostate cancer, driven by factors like an aging population, evolving lifestyles, and increased awareness and screening efforts, has created a substantial demand for prostate cancer diagnostics. One common type of cancer is prostate cancer, which originates in the prostate gland, a small gland found in men below the bladder. Seminal vesicles are made by the prostate gland, which nourishes and transports sperm. The condition develops when the cells in the prostate gland undergo abnormal growth and multiplication, forming a tumor. The tumor can grow to nearby tissues, organs, or other body parts if left untreated through metastasis. Prostate cancer is primarily diagnosed in older men, with the risk increasing. While it is most commonly seen in men over 65, it can also affect younger individuals, although less frequently.

There is still no recognized etiology for prostate cancer, but certain factors contribute to its development. These include age, family history of prostate cancer, race (with African American men having a higher risk), and specific genetic mutations. Lifestyle factors like diet, obesity, and exposure to certain substances may also play a role, although More study is required to comprehend their influence completely. Prostate cancer is a significant health concern globally, and efforts are focused on early detection and effective treatment strategies. Screening methods such as prostate-specific antigen (PSA) tests, digital rectal exams (DRE), and imaging techniques aid in diagnosing and monitoring the disease. The prostate cancer therapies available are surgery, radiation therapy, hormone therapy, chemotherapy, and targeted therapies, depending on the cancer's stage and features.

Test Type Insights

The market is segmented into preliminary tests and confirmatory tests. Preliminary tests, which include PSA tests, free PSA tests, total PSA tests, and other initial diagnostic measures, are used for initial screening. If these preliminary results are abnormal, confirmatory tests such as the PCA3 test, trans-rectal ultrasound, and biopsy are required to validate the diagnosis. The confirmatory tests segment dominates the market due to the increasing incidence of prostate cancer, particularly when it has spread to other organs or involves genital and urinary tract infections. According to a May 2023 American Cancer Society article, abnormal preliminary test results necessitate additional confirmatory testing, which helps in assessing the risk of metastasis. This rising prevalence of prostate cancer drives the demand for confirmatory tests, thereby boosting market growth as these tests are essential for accurate diagnosis and treatment planning.

Request Customizationto receive a tailored report.

Type Insights

In the market, the type is segmented into adenocarcinoma, interstitial cell carcinoma, and others. Out of which the adenocarcinoma dominates the type segment in the market. The most common type of prostate cancer is adenocarcinoma, representing more than 95% of cases, while rarer forms like interstitial cell carcinoma are much less frequent. Symptoms of prostate adenocarcinoma typically include trouble urinating, weak urine flow, occasional blood in the urine, difficulty fully emptying the bladder, and persistent lower back pain. Patients may exhibit signs of an enlarged prostate and abnormal results from a digital rectal exam (DRE), although the DRE has limited sensitivity and specificity. According to an article from NCBI in June 2023, adenocarcinoma of the prostate is the second most prevalent cancer in men worldwide and ranks third in cancer-related deaths in the U.S. Mortality rates from prostate cancer have been on the decline, especially in the U.S., due to improvements in screening and additional therapies. The dominance of adenocarcinoma in the prostate cancer diagnostics market is evident from its higher prevalence compared to other types of prostate cancer. Consequently, efforts in diagnostics and market focus are heavily geared towards adenocarcinoma due to its high incidence and the necessity for effective screening and treatment approaches.

End User Insights

In the market, the outpatient facilities segment has emerged as the dominant end-use category. This shift is driven by several factors, including the increasing preference for less invasive procedures and the growing demand for convenient, cost-effective diagnostic options. Outpatient facilities, such as specialized diagnostic centers and clinics, offer targeted prostate cancer testing services, including imaging and biopsies, in a more streamlined and efficient manner compared to hospitals. The emphasis on reducing hospital visits and the ability to perform diagnostics with shorter wait times have contributed to the growth of outpatient settings. Additionally, advancements in technology and the rise of minimally invasive diagnostic techniques make outpatient facilities an attractive choice for patients and healthcare providers alike. As a result, outpatient facilities have become a key player in the prostate cancer diagnostics market, reflecting the broader trend towards decentralized and patient-centric care.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global prostate cancer diagnostics market shareholder and is estimated to grow at a CAGR of 12.2% over the forecast period. The largest market share was held by the prostate cancer diagnostics market in North America due to the rising prevalence of prostate cancer and increasing government initiatives to enhance disease diagnosis. For instance, the National Cancer Institute implemented various programs to enhance the research efforts for early detection and treatment of the disease. A few of its programs include biomarker research groups, which promote research on biomarkers. It also manages the Early Detection Research Network, an initiative by the National Cancer Institute that collaborates with similar organizations to discover and validate early disease detection using biomarkers.

Additionally, technological advancements in diagnostic tests are expected to fuel market growth during the forecast period. According to the National Cancer Institute (NCI), researchers are currently testing and utilizing Artificial Intelligence (AI) to improve the diagnosis of prostate cancer. AI tools identify suspicious areas seen during an MRI scan, requiring biopsies to confirm the presence of malignant cells. AI tools are also being tested to enhance the analysis of biopsy samples, thereby facilitating accurate and efficient results.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Prostate Cancer Diagnostics Market Trends

Europe is anticipated to exhibit a CAGR of 12.5% over the forecast period. According to Eurostat, prostate cancer is Europe's third most common cause of death. A rise in prostate cancer incidence in European countries has resulted in high demand for prostate cancer diagnostics, leading to increased production of such diagnostic tools. Furthermore, various awareness programs, such as European Prostate Cancer Awareness Day, celebrated on 27 September, increase demand for diagnostics. The cost of production in European countries is relatively lower than in the U.S., thereby increasing the profit margins for companies.

Moreover, the number of initiatives to raise awareness about the disease in the region is anticipated to fuel market growth. For instance, in 2019, the European Association of Urology initiated the European Prostate Cancer Awareness program to increase awareness about the early detection of prostate cancer. This awareness program covers various topics, including overtreatment, overdiagnosis, and the consequences of late detection. In addition, the incidence of prostate cancer in the region is expected to fuel market growth. According to the European Association of Urology, over 2 million individuals in Europe were diagnosed with the disease in 2018, and about 92,000 men die from it each year. The yearly cost incurred due to prostate cancer accounts for USD 10.6 billion, indicative of the rising disease prevalence.

Asia Pacific Prostate Cancer Diagnostics Market Trends

In Asia-Pacific, in the past few decades, the incidence of prostate cancer was reported to be low in the Asia-Pacific countries compared with other countries worldwide. However, economic growth and sociocultural changes led to an increased life expectancy, and a Westernized lifestyle has increased prostate cancer incidence in Asian countries. The increasing prevalence of prostate cancer and awareness campaigns in various Asia-Pacific countries are expected to increase the demand for prostate cancer diagnostics. The market is forecasted to grow exponentially in the Asia Pacific region owing to an increase in the aging population, a rise in migration of the rural population, easy access to medical facilities, and changing lifestyles.

The Latin American prostate cancer diagnostics market is experiencing significant growth and is forecasted to continue expanding in the coming years. Factors such as the increasing prevalence of prostate cancer, advancements in diagnostic technologies, and supportive government initiatives drive the market's growth. With a rising focus on early detection and improved cancer care, the demand for accurate and efficient prostate cancer diagnostics is expected to increase, leading to market expansion and improved patient outcomes in the region.

List of Key and Emerging Players in Prostate Cancer Diagnostics Market